Plain-English translation of NCT07209410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether brimonidine tartrate 0.025% eye drops can reduce eye redness in people who are already using a combination glaucoma medication called netarsudil 0.02%/latanoprost 0.005%. Many patients experience significant redness as a side effect from their glaucoma treatment, and this study wants to see if adding this medication can help improve comfort and appearance without affecting how well the glaucoma is controlled.
A common side effect of one popular glaucoma treatment is significant eye redness, which can bother patients and sometimes lead them to stop using their medication. This trial aims to find out whether this medication can safely reduce that redness and improve quality of life for people managing glaucoma.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would continue your current glaucoma medication and add brimonidine tartrate eye drops to your daily routine. During the study, you'll have visits where the research team will photograph your eye to document redness and ask you questions about your satisfaction with the treatment. The study involves switching to or confirming you're on the specific combination medication, then adding the new drops while the team monitors how well the redness improves and how you feel about the results.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Enrollment target
~35 participants
Started
November 2025
Primary completion
December 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Crystal Remington Optometrist, OD
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.